Lastifluno

Azelastine Hydrochloride and Fluticasone Propionate, the active ingredients in Lastifluno, are an antihistamine and a corticosteroid presented as a nasal spray for intranasal use. They treat seasonal and perennial allergic rhinitis by reducing nasal inflammation and histamine‑mediated symptoms in adults and children, providing relief from sneezing, itching, and congestion.

GNH USA supplies Lastifluno as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lastifluno combines an antihistamine and a corticosteroid to manage allergic rhinitis and related nasal symptoms.

Seasonal allergic rhinitis: reduces sneezing, itching and nasal discharge. Perennial allergic rhinitis: alleviates chronic nasal congestion and watery eyes. Nasal congestion due to allergy: decreases mucosal swelling for easier breathing.

Adverse reactions reported with intranasal azelastine‑fluticasone therapy are generally mild to moderate.

Common Side Effects: - Bitter taste in the mouth - Nasal irritation or burning sensation - Headache - Sneezing shortly after use - Throat irritation

Serious or Rare Side Effects: - Epistaxis (nosebleed) - Nasal septum perforation - Severe allergic reaction (anaphylaxis) - Vision changes - Persistent nasal dryness

Before using Lastifluno, consider the following precautions.

Pregnancy: consult a healthcare provider before use. Breastfeeding: limited data; use only if benefit outweighs potential risk. Age restrictions: safety not established in children under 2 years. Concomitant nasal surgery: postpone use until postoperative healing is complete. Hypersensitivity: avoid if known allergy to azelastine, fluticasone, or excipients. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Potential drug interactions should be reviewed prior to initiating therapy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase systemic exposure to fluticasone. - Monoamine oxidase inhibitors (MAOIs): possible additive central nervous system effects with azelastine.

Moderate Interactions (Monitor Closely):\n- Anticholinergic agents: may exacerbate nasal dryness. - Other intranasal corticosteroids: risk of cumulative steroid exposure. - Alcohol: may enhance drowsiness associated with azelastine.